The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of health insurance industry veteran Wendy Arnone to its Board of Directors. ...
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach for CMT1A and CMT1B, two common forms of the disease. ...
Charcot-Marie-Tooth Association (CMTA) Alliance Partner, NMD Pharma, announced the publication of comprehensive data sets demonstrating for the first time the ability of CIC-1 inhibition to restore muscle function in patients suffering from neuromuscular junction (NMJ) transmission deficits. These data are ...
The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, is pleased to announce the appointment of Bernard Coulie, M.D., Ph.D., and Kevin Marks to its Board of ...
The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT)
GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and ...